Home
About
Our Strategy
Management Team
Scientific Advisors
Vive la Liberté
Pipeline
Pipeline Introduction
TRM - 201
TRM - 359
News
Work With Us
Contact
Home
About
Our Strategy
Management Team
Scientific Advisors
Vive la Liberté
Pipeline
Pipeline Introduction
TRM - 201
TRM - 359
News
Work With Us
Contact
Focused
On providing non-opioid pain therapies for rare diseases
Latest News
Featured
Feb 15, 2018
Tremeau Completes $5.2 Million Equity Raise to Fund Non-Opioid Pain Treatments for Rare Diseases
Feb 15, 2018
Feb 15, 2018
Jan 2, 2018
Tremeau Pharmaceuticals to Present at the 2018 Biotech Showcase in San Francisco
Jan 2, 2018
Jan 2, 2018
Dec 12, 2017
Tremeau and FDA Agree on Phase III Plan for Rofecoxib as Non-Opioid Pain Treatment for Hemophilic Arthropathy
Dec 12, 2017
Dec 12, 2017
Nov 21, 2017
FDA Grants Orphan Drug Designation for TRM-201 (rofecoxib) for the Treatment of Hemophilic Arthropathy
Nov 21, 2017
Nov 21, 2017
Nov 21, 2017
APNews: Startup could bring back Vioxx for hemophilia
Nov 21, 2017
Nov 21, 2017
Nov 8, 2017
HHS Acting Secretary Declares Public Health Emergency to Address National Opioid Crisis
Nov 8, 2017
Nov 8, 2017
Oct 13, 2017
Steps the U.S. government should take right now against the opioid epidemic
Oct 13, 2017
Oct 13, 2017
Oct 2, 2017
Senator Calls on Insurers to Improve Access to Non-Opioid Pain Treatments
Oct 2, 2017
Oct 2, 2017
Sep 15, 2017
FDA is committed to new classes of pain medicines without the same risks as opioids
Sep 15, 2017
Sep 15, 2017
Sep 15, 2017
Use and frequency of oral opioids are the greatest predictor of subsequent opioid addiction
Sep 15, 2017
Sep 15, 2017
